Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0654 USD | -6.23% | -4.38% | -6.29% |
Apr. 01 | Willow Biosciences Narrows 2023 Loss YOY | MT |
Mar. 29 | Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 19
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Travis Doupe
DFI | Director of Finance/CFO | - | 19-04-11 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
Simon Hickling
PRN | Corporate Officer/Principal | - | - |
Sony Gill
SEC | Corporate Secretary | 48 | 19-04-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 23-02-20 |
Donald Archibald
BRD | Director/Board Member | 63 | 19-04-11 |
Director/Board Member | 51 | 19-04-11 | |
Raffi Asadorian
BRD | Director/Board Member | 54 | 23-05-10 |
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,222,030 | 92,512,715 ( 72.72 %) | 0 | 72.72 % |
Company contact information
Willow Biosciences, Inc.
1201 5th Street South West Suite 202
T2R 0Y6, Calgary
+
http://www.willowbio.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-2.65% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- WLLW Stock
- CANS.F Stock
- Company Willow Biosciences Inc.